The effectiveness of cetuximab and panitumumab when combined with FOLFIRI in second-line treatment of KRAS wild type metastatic colorectal cancers. Single centre experience

Abstract

Panitumumab and cetuximab are monoclonal antibodies known to be effective in metastatic colorectal cancer (mCRC). Although the survival benefits when combined with chemotherapy have been determined, there are no studies comparing the two agents with chemotherapy in the second-line treatment. In this study, we aimed to compare the efficacy of cetuximab vs panitumumab in patients who previously received chemotherapy. Who progressed after first-line treatment for K-ras wild type mCRC were analyzed. The efficacy of cetuximab vs panitumumab on overall survival (OS) and progression-free survival (PFS) when combined with FOLFIRI regimen was compared retrospectively. Median PFS was 6.9 months in the cetuximab group and 4.7 months in the panitumumab group. Median OS cetuximab and panitumumab groups were 18.4 and 12.2 months, respectively. In the second-line treatment of K-ras wild type mCRC, both PFS and OS were found to be longer in patients receiving cetuximab than in patients receiving panitumumab, but no statistically significant difference was found.

Keywords:

• Colorectal cancers
• cetuximab
• panitumumab
• K-ras
• PFS
• OS

Disclosure statement

The authors declare no conflict of interest with regard to the present study.

Ethical approval

This study was approved by Ethical Committy of (Decision number: (20-3 T/44)) All patients gave written informed consent.

Additional information

Notes on contributors

Pınar Gürsoy

Specialist Dr Pınar Gürsoy, as assistant in Medical Oncology at Ege University Faculty of Medicine. He made Writing, statistics and design of the article.

Burcu Çakar

Associate Professor Burcu Cakar has received her specialty in Medical Oncology from Ege University Faculty of Medicine and she is still continuing as Associate Professor at the same university. She made a great contribution to me in recruiting patients and statistical evaluation.

Elvina Almuradova

Specialist Dr Elvina Almurodova, as assistant in Medical Oncology at Ege University Faculty of Medicine. She helped part in entering patient data into the system.

Murat Karateke

Specialist Dr Murat Karateke, as assistant in Medical Oncology at Ege University Faculty of Medicine. He helped part in entering patient data into the system.

Başak Doğanavşargil

Professor Dr Başak Doğanavşargil, as professor in Patology Department at Ege University Faculty of Medicine. She helped part in consideration of patological datas and EGFR results.

Murat Sezak

Associate Professor Murat Sezak, as associate professor in Patology Department at Ege University Faculty of Medicine. He helped part in consideration of patological datas and EGFR results.

Mustafa Harman

Professor Dr Mustafa Harman, as radiologist in Radiology Department at Ege University Faculty of Medicine. He helped part in evaluation of radiological datas.

Bülent Karabulut

Professor Dr Bülent Karabulut, as professor doctor in Medical Oncology Department at Ege University Faculty of Medicine. He made a great contribution to the evaluation of patient data.